Published in Circulation on April 09, 2002
Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ (2008) 2.98
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation (2012) 2.76
Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol (2011) 1.59
Mean platelet volume and long-term mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol (2012) 1.49
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A (2002) 1.39
A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol (2008) 1.29
Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J (2005) 1.15
Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. Int J Endocrinol (2011) 1.12
Platelet hyperreactivity: predictive and intrinsic properties. Hematol Oncol Clin North Am (2007) 1.06
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood (2006) 1.03
Antiplatelet resistance and thromboembolic complications in neurointerventional procedures. Front Neurol (2011) 1.01
Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2008) 1.01
The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow p(2)y(12) assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation. Korean Circ J (2009) 0.99
Aspirin Resistance in healthy drug-naive men versus women (from the Heredity and Phenotype Intervention Heart Study). Am J Cardiol (2009) 0.97
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol (2009) 0.97
Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol (2008) 0.96
Clinical importance of aspirin and clopidogrel resistance. World J Cardiol (2010) 0.95
Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med (2008) 0.95
Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation (2002) 0.95
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis (2012) 0.93
Inhibition of thromboxane A2-induced arrhythmias and intracellular calcium changes in cardiac myocytes by blockade of the inositol trisphosphate pathway. J Pharmacol Exp Ther (2009) 0.93
Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome. Hypertension (2012) 0.92
Clinical determinants of aspirin resistance in diabetes. Diabetes Res Clin Pract (2010) 0.90
Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets. Br J Clin Pharmacol (2014) 0.88
Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. Nat Clin Pract Cardiovasc Med (2009) 0.88
The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J (2004) 0.87
Biological basis and clinical implications of acetylsalicylic acid resistance. Can J Cardiol (2006) 0.87
Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. Nat Rev Endocrinol (2010) 0.86
Platelet kainate receptor signaling promotes thrombosis by stimulating cyclooxygenase activation. Circ Res (2009) 0.84
Aspirin and clopidogrel response variability: review of the published literature. Tex Heart Inst J (2008) 0.84
Aspirin resistance. BMJ (2004) 0.84
Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components. Metab Syndr Relat Disord (2009) 0.84
Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean J Intern Med (2004) 0.83
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device. J Thromb Thrombolysis (2014) 0.83
Aspirin resistance. Adv Hematol (2009) 0.83
Aspirin resistance in children with heart disease at risk for thromboembolism: prevalence and possible mechanisms. Pediatr Cardiol (2007) 0.83
Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein. Br J Pharmacol (2008) 0.82
The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can J Cardiol (2007) 0.81
Aspirin resistance in patients with acute ischemic stroke. J Neurol (2011) 0.81
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. Circ Res (2013) 0.81
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg (2011) 0.81
Platelet content of nitric oxide synthase 3 phosphorylated at Serine 1177 is associated with the functional response of platelets to aspirin. PLoS One (2013) 0.80
Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. J Am Heart Assoc (2014) 0.80
Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents. Drugs R D (2010) 0.79
Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease. Thromb Res (2009) 0.79
Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders. J Aging Res (2012) 0.79
Network reconstruction of platelet metabolism identifies metabolic signature for aspirin resistance. Sci Rep (2014) 0.79
Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids (2013) 0.79
Sex differences in urinary biomarkers of vascular and endothelial function in HIV-infected persons receiving antiretroviral therapy. Antivir Ther (2011) 0.79
Impact of platelet transfusion on survival of patients with intracerebral hemorrhage after administration of anti-platelet agents at a tertiary emergency center. PLoS One (2014) 0.79
Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease. Syst Rev (2014) 0.79
Aspirin resistance and other aspirin-related concerns. Neurol Sci (2015) 0.78
Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postepy Kardiol Interwencyjnej (2015) 0.78
Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. Mediators Inflamm (2014) 0.78
Pharmacological characterization of 1-nitrosocyclohexyl acetate, a long-acting nitroxyl donor that shows vasorelaxant and antiaggregatory effects. J Pharmacol Exp Ther (2012) 0.78
Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart (2008) 0.78
Effect of opium addiction on aspirin resistance in stable angina pectoris. Addict Health (2014) 0.78
Emerging therapies for acute coronary syndromes. Front Pharmacol (2011) 0.78
Risk Factors for Nonplatelet Thromboxane Generation After Coronary Artery Bypass Graft Surgery. J Am Heart Assoc (2016) 0.78
Antiplatelet Resistance-Does it Exist and How to Measure it? Clin Med Cardiol (2009) 0.78
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc Health Risk Manag (2009) 0.77
The Effect of Xuefuzhuyu Oral Liquid on Aspirin Resistance and Its Association with rs5911, rs5787, and rs3842788 Gene Polymorphisms. Evid Based Complement Alternat Med (2015) 0.77
Effect of assay specificity on the association of urine 11-dehydro thromboxane B2 determination with cardiovascular risk. J Thromb Haemost (2012) 0.77
Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance: a case report. J Extra Corpor Technol (2009) 0.77
Acute coronary syndromes: should women receive less antithrombotic medication than men? Heart (2004) 0.77
Aspirin resistance. Circulation (2002) 0.77
Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. J Blood Med (2010) 0.77
Effect of glucose or fat challenge on aspirin resistance in diabetes. Int J Endocrinol (2011) 0.77
Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study. Heart Vessels (2010) 0.77
The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials. Proc (Bayl Univ Med Cent) (2005) 0.76
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med (2011) 0.76
Cardiac thromboxane A2 receptor activation does not directly induce cardiomyocyte hypertrophy but does cause cell death that is prevented with gentamicin and 2-APB. BMC Pharmacol Toxicol (2014) 0.76
Aspirin resistance: Fact or fiction? A point of view. World J Cardiol (2010) 0.76
Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease. World J Diabetes (2014) 0.76
Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity. Nutr Metab Cardiovasc Dis (2013) 0.75
Aspirin prophylaxis for the prevention of thrombosis: expectations and limitations. Thrombosis (2012) 0.75
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease. Tex Heart Inst J (2016) 0.75
Mean Platelet Volume as a Predictor of One-Year Major Adverse Cardiac Events following Elective Percutaneous Coronary Interventions. J Tehran Heart Cent (2014) 0.75
Towards personalized medicine based on platelet function testing for stent thrombosis patients. Thrombosis (2012) 0.75
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. J Cell Mol Med (2010) 0.75
Aspirin resistance: A fact or a myth? Exp Clin Cardiol (2005) 0.75
Patient with recent coronary artery stent requiring major non cardiac surgery. Indian J Anaesth (2009) 0.75
Aspirin resistance and its implications in clinical practice. MedGenMed (2005) 0.75
Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. Physiol Genomics (2010) 0.75
Establishing a predictive model for aspirin resistance in elderly Chinese patients with chronic cardiovascular disease. J Geriatr Cardiol (2016) 0.75
Reasons for resistance to aspirin in cardiovascular disease. Circulation (2002) 0.75
Inflammation and platelet activation in peripheral arterial occlusive disease. Int J Angiol (2007) 0.75
Current developments in anti-platelet therapy. Wien Med Wochenschr (2006) 0.75
Medicinal Herbals with Antiplatelet Properties Benefit in Coronary Atherothrombotic Diseases. Thrombosis (2016) 0.75
The implications of aspirin resistance in renal failure. NDT Plus (2008) 0.75
Critical Overview on the Benefits and Harms of Aspirin. Pharmaceuticals (Basel) (2010) 0.75
Resisting aspirin. Circulation (2002) 0.75
Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease. J Lab Clin Med (2006) 0.75
Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future. Biomark Insights (2008) 0.75
Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside. Biologics (2008) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Defining obesity cut points in a multiethnic population. Circulation (2007) 4.42
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet (2008) 4.37
Need for expertise based randomised controlled trials. BMJ (2005) 4.34
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med (2012) 4.32
Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med (2013) 4.27
Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation (2005) 4.21
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res (2006) 3.80
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 3.75
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. J Hypertens (2014) 3.66
Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J (2008) 3.64
Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J (2008) 3.52
The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology (2008) 3.47
Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 3.43
Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J (2008) 3.38
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
Newly identified events in the RE-LY trial. N Engl J Med (2010) 3.35
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol (2010) 3.26
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation (2006) 3.22
Dietary patterns and the risk of acute myocardial infarction in 52 countries: results of the INTERHEART study. Circulation (2008) 3.19
Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation (2003) 3.15
WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE). Bull World Health Organ (2005) 3.09
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA (2007) 3.09
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J (2002) 3.05
Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 3.02
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation (2002) 2.89